JNH — Jack Nathan Medical Income Statement
0.000.00%
Last trade - 00:00
- CA$4.35m
- CA$10.68m
- CA$15.49m
- 11
- 59
- 12
- 17
2019 January 31st | 2020 January 31st | 2021 January 31st | C2022 January 31st | 2023 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.93 | 3.62 | 3.85 | 9.64 | 15.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 2.07 | 3.46 | 13.9 | 17.7 | 22.3 |
Operating Profit | 0.859 | 0.153 | -10 | -8.03 | -6.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 2.78 | -1.38 | -10.3 | -8.23 | -6.99 |
Provision for Income Taxes | |||||
Net Income After Taxes | 2.11 | -1.36 | -9.91 | -8.02 | -6.9 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 2.11 | -1.36 | -9.9 | -7.81 | -6.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 2.11 | -1.36 | -9.9 | -7.81 | -6.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.027 | -0.018 | -0.082 | -0.086 | -0.07 |
Dividends per Share |